Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

In April 2010, the European Medicines Agency Committee for Medicinal Products for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4 inhibitor, for the “maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV(1) postbronchodilator less than 50% pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Giembycz, Mark A, Field, Stephen K
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915539/
https://www.ncbi.nlm.nih.gov/pubmed/20689641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915539/
https://www.ncbi.nlm.nih.gov/pubmed/20689641

Ejemplares similares